Skip to main content
. 2022 Nov 21;10:984375. doi: 10.3389/fcell.2022.984375

FIGURE 5.

FIGURE 5

Morphine-mediated upregulation of miR-23a in ADEVs involves mu receptor and hnRNP A2/B1. (A,B) Astrocytes were pretreated with naltrexone (10 μM) for 1 h, followed by 24 h exposure to morphine. The expression of miR-23a in astrocytes (A) and ADEVs (B) was assessed using real-time PCR. Each set of results was quantified upon three independent experiments. (C) Representative western blot images of hnRNP A2/B1 expression in the lysates of cells and ADEVs from astrocytes exposed to morphine for various time points (1–24 h). (D,E) Representative western blot images of hnRNP A2/B1 expression in the lysates of cells (D) or ADEVs (E) from astrocytes transfected with control siRNA or si-hnRNP A2/B1 followed by morphine exposure. Each set of results was quantified upon three independent experiments. (F,G) Astrocytes were transfected with either control siRNA or si-hnRNP A2/B for 24 h, followed by morphine exposure for 24 h. The expression of miR-23a in astrocytes (F) and ADEVs (G) was assessed using real-time PCR. Each set of results was quantified upon three independent experiments. All data are presented as mean ± SD, *p < 0.05, **p < 0.01, ***p < 0.001 vs. si-ctl-control group; #p < 0.05, ##p < 0.01 vs. si-ctl-morphine group using one-way ANOVA analysis.